MBG453C
Total Payments
$31,723
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $31,723 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31,723 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE II MULTI-CENTER, SINGLE ARM, SAFETY AND EFFICACY STUDY OF MBG453 IN COMBINATION WITH AZACITIDINE AND VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS UNFIT FOR CHEMOTHERAPY | Novartis Pharmaceuticals Corporation | $31,723 | 0 |
Top Doctors Receiving Payments for MBG453C
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $31,723 | 5 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $31,723
- Total Doctors 0
- Transactions 5
About MBG453C
MBG453C is a drug associated with $31,723 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $31,723 was paid across 5 transactions to 0 doctors.
The most common payment nature for MBG453C is "Unspecified" ($31,723, 100.0% of total).
MBG453C is associated with 1 research study, including "A PHASE II MULTI-CENTER, SINGLE ARM, SAFETY AND EFFICACY STUDY OF MBG453 IN COMBINATION WITH AZACITIDINE AND VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS UNFIT FOR CHEMOTHERAPY" ($31,723).